NCT04937816View on ClinicalTrials.gov

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

CompletedOBSERVATIONAL
Enrollment

16,746

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 13, 2021

Study Completion Date

July 13, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Placebo

DRUG

Empagliflozin

Empagliflozin once daily

Trial Locations (1)

55218

Boehringer Ingelheim, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04937816 - This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations | Biotech Hunter | Biotech Hunter